A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
- Conditions
- B-cell Lymphoma, AdultSolid Tumor, AdultAdvanced Cancer
- Interventions
- Registration Number
- NCT03922204
- Lead Sponsor
- Merus N.V.
- Brief Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.
- Detailed Description
Study Design: This open label, multicenter, first in human study consists of 2 parts. Part 1 is a dose escalation to find the recommended dose of MCLA-145 in monotherapy or in combination with pembrolizumab.
Part 2 is a dose expansion to confirm the dose of MCLA-145, alone or in combination through further evaluation of safety, tolerability, Pk, preliminary antitumor activity, and functional target engagement.
The study includes three periods: Screening (up to 28 days prior to the first dose of study drug); Treatment (first dose of study drug with treatment cycles of 28 days for patients treated Q2W and 21 days for patients treated Q3W); Safety Follow-up (30 and 90 days after the last dose) including survival follow-up checks every 2 months up to 12 months after the last dose.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
- Histologically or cytologically confirmed advanced or recurrent/metastatic solid tumors or B-cell lymphomas, that are considered non-amenable to surgery or other curative treatments or procedures (if applicable)
- Measureable disease per RECIST v1.1 or Lugano Criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Received prior standard therapy for advanced or recurrent/metastatic disease as applicable to tumor type
- Received a maximum of 4 prior systemic treatment regimens (inclusive of chemotherapy, immunotherapy, and targeted therapy regimens) for advanced or recurrent/metastatic disease
- Life expectancy of ≥12 weeks, as per investigator judgement
- The following B-cell neoplasms: Burkitt lymphoma, lymphoblastic leukemia/lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia
- Prior therapy containing an anti-PD-L1 agent or T-cell agonist
- Current serious illness or medical condition including, but not limited to uncontrolled active infection
- Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting MCLA-145
- Prior ≥ Grade 3 immune-mediated AEs with anti-PD-1 therapy
- History of any grade immune-mediated ocular AEs.
- Known hypersensitivity or severe reaction to any component of MCLA-145 or formulation components
- Participants who have active or inactive autoimmune disease or syndrome (eg, rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease) that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group B Combination Treatment Pembrolizumab (Keytruda) Patients in Group B will be treated with MCLA-145 in Combination with pembrolizumab 200mg Q3W. MCLA-145 MCLA-145 In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 (either Q2W for those patients in treatment at the time of Amendment #4 or Q3W with Amendment #4 approval). Treatment will be with MCLA-145 (monotherapy) for Group A, or in combination with pembrolizumab for Group B, until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 either in monotherapy (Group A) or in combination with pembrolizumab (Group B) at the recommended phase II dose every 3 weeks. The duration of each treatment cycle is 21 days Group B Combination Treatment MCLA-145 Patients in Group B will be treated with MCLA-145 in Combination with pembrolizumab 200mg Q3W.
- Primary Outcome Measures
Name Time Method Number of patients with Dose Limiting Toxicities first 28 days of treatment Number of patients with Adverse Events and Serious Adverse Events up to 90 days post-last dose
- Secondary Outcome Measures
Name Time Method Overall response rate (ORR) Every 8 to 12 weeks until study ends, approximately 4 years Duration of response ( DOR) Every 8 to 12 weeks until study ends, approximately 4 years Disease control rate ( DCR) Every 8 to 12 weeks until study ends, approximately 4 years Progression Free Survival ( PFS) Every 8 to 12 weeks until study ends, approximately 4 years Incidence of anti-drug antibodies against MCLA-145 12 months Peak plasma concentration [Cmax] 12 months Area under the plasma concentration versus time curve [AUC] 12 months Half-life [t1/2] 12 months
Trial Locations
- Locations (8)
Moores Cancer Centre
🇺🇸La Jolla, California, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
University Hospital Antwerp
🇧🇪Antwerp, Edegem, Belgium
Universitair Ziekenhuis Gent
🇧🇪Gent, Belgium
Netherlands Cancer Institute
🇳🇱Amsterdam, Netherlands
Hospital Universitario Fundarcion Jimenez Diaz
🇪🇸Madrid, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain